132 related articles for article (PubMed ID: 12432053)
1. Osteoprotegerin deficiency and juvenile Paget's disease.
Hofbauer LC; Schoppet M
N Engl J Med; 2002 Nov; 347(20):1622-3; author reply 1622-3. PubMed ID: 12432053
[No Abstract] [Full Text] [Related]
2. Osteoprotegerin deficiency and juvenile Paget's disease.
Whyte MP; Obrecht SE; Finnegan PM; Jones JL; Podgornik MN; McAlister WH; Mumm S
N Engl J Med; 2002 Jul; 347(3):175-84. PubMed ID: 12124406
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes.
Shin JY; Shin YG; Chung CH
Diabetes Care; 2006 Jul; 29(7):1664-6. PubMed ID: 16801598
[No Abstract] [Full Text] [Related]
4. Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling.
Whyte MP
Ann N Y Acad Sci; 2006 Apr; 1068():143-64. PubMed ID: 16831914
[TBL] [Abstract][Full Text] [Related]
5. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
Shipman CM; Croucher PI
Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
[TBL] [Abstract][Full Text] [Related]
6. Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL.
Middleton-Hardie C; Zhu Q; Cundy H; Lin JM; Callon K; Tong PC; Xu J; Grey A; Cornish J; Naot D
J Bone Miner Res; 2006 Mar; 21(3):438-45. PubMed ID: 16491292
[TBL] [Abstract][Full Text] [Related]
7. RANKing the importance of measles virus in Paget's disease.
Ross FP
J Clin Invest; 2000 Mar; 105(5):555-8. PubMed ID: 10712423
[No Abstract] [Full Text] [Related]
8. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation.
Sun SG; Lau YS; Itonaga I; Sabokbar A; Athanasou NA
J Pathol; 2006 May; 209(1):114-20. PubMed ID: 16482498
[TBL] [Abstract][Full Text] [Related]
9. [Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases].
Hofbauer LC; Heufelder AE
Dtsch Med Wochenschr; 2001 Feb; 126(6):145-50. PubMed ID: 11233883
[No Abstract] [Full Text] [Related]
10. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
[TBL] [Abstract][Full Text] [Related]
11. Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis.
Hofbauer LC; Heufelder AE; Erben RG
J Rheumatol; 2001 Apr; 28(4):685-7. PubMed ID: 11327234
[No Abstract] [Full Text] [Related]
12. Osteoprotegerin is expressed in colon carcinoma cells.
Pettersen I; Bakkelund W; Smedsrød B; Sveinbjørnsson B
Anticancer Res; 2005; 25(6B):3809-16. PubMed ID: 16309167
[TBL] [Abstract][Full Text] [Related]
13. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
Yeung RS
J Rheumatol; 2004 May; 31(5):844-6. PubMed ID: 15124240
[No Abstract] [Full Text] [Related]
14. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
[TBL] [Abstract][Full Text] [Related]
15. Detection of osteoprotegerin and TNF-alpha mRNA in ankylotic Stapes footplates in connection with measles virus positivity.
Karosi T; Jókay I; Kónya J; Szabó LZ; Pytel J; Jóri J; Szalmás A; Sziklai I
Laryngoscope; 2006 Aug; 116(8):1427-33. PubMed ID: 16885748
[TBL] [Abstract][Full Text] [Related]
16. [Molecular mechanism of bone metabolism].
Kotake S; Utagawa N; Suda T; Kamatani N
Nihon Naika Gakkai Zasshi; 2000 Oct; 89(10):2046-53. PubMed ID: 11215116
[No Abstract] [Full Text] [Related]
17. RANK ligand and the regulation of skeletal remodeling.
Bell NH
J Clin Invest; 2003 Apr; 111(8):1120-2. PubMed ID: 12697730
[No Abstract] [Full Text] [Related]
18. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
Ikeda T; Utsuyama M; Hirokawa K
J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
[TBL] [Abstract][Full Text] [Related]
19. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha.
Wada N; Maeda H; Yoshimine Y; Akamine A
Bone; 2004 Sep; 35(3):629-35. PubMed ID: 15336598
[TBL] [Abstract][Full Text] [Related]
20. RANK ligand and osteoprotegerin: emerging roles in mucosal inflammation.
Ashcroft AJ; Carding SR
Gut; 2005 Sep; 54(9):1345-6. PubMed ID: 16099805
[No Abstract] [Full Text] [Related]
[Next] [New Search]
